| Cat.No. | Name | Information |
|---|---|---|
| M1766 | PF-04217903 | PF-04217903 (PF-4217903) is a novel ATP-competitive small molecule inhibitor of c-Met kinases with the IC50 values from 3.1 nM to142 nM. |
| M2080 | Capmatinib (INCB28060) | Capmatinib (INCB28060) is a novel inhibitor of c-MET kinase with IC50 of 0.13 nM. |
| M1765 | Crizotinib (PF-02341066) | Crizotinib (PF-02341066) is a potent, orally bioavailable, ATP-competitive small-molecule inhibitor of c-Met kinase and ALK (anaplastic lymphoma kinase) with IC50 values to be 4 and 25 nM for C-Met and ALK resepectively. |
| M1757 | XL-184 | XL184 is a small molecule inhibits multiple receptor tyrosine kinases, specifically MET and VEGFR2 with IC50 values of 0.035 and 1.8 nM for VEGFR2 and Met respectively. |
| M1758 | Foretinib | Foretinib (XL880, GSK1363089) is a multi-targeted inhibitor of c-Met and vascular endothelial growth factor receptor 2 (VEGFR2) with IC50 value of 0.4 nM for c-MET. |
| M25260 | Rilotumumab | Rilotumumab (AMG 102) is an anti-HGF (anti-hepatocyte growth factor) monoclonal antibody, inhibits HGF/MET-driven signaling. Rilotumumab shows anti-tumor activity, and can be used in castration-resistant prostate cancer (CRPC) and solid tumor research. |
| M24631 | Emibetuzumab | Emibetuzumab (LY2875358) is a humanized bivalent MET antibody (IgG4 type). Emibetuzumab shows high neutralization and internalization activities, resulting in inhibition of both HGF-dependent and HGF-independent MET pathway activation and tumor growth. Emibetuzumab can be used in study of cancer. |
| M24554 | Onartuzumab | Onartuzumab (MetMAb) is a unique, humanized and affinity-matured monovalent (one-armed) monoclonal antibody against the MET receptor. Onartuzumab potently inhibits HGF binding and receptor phosphorylation and signaling. Onartuzumab has antibody-like pharmacokinetics and antitumor activity. |
| M21574 | TAM&Met-IN-1 | TAM&Met-IN-1 is a potent TAM and c-Met inhibitor with IC50 of 6.1 nM, 13.2 nM and 21.6 nM against AXL, MER and TYRO3, respectively. TAM&Met-IN-1 can be used in anticancer research. |
| M20747 | BAY-474 | BAY-474 is an inhibitor of tyrosine-protein kinase c-Met and can act as an epigenetics probe. |
| M20743 | AMG-1 | AMG-1 (c-Met/RON Dual Kinase Inhibitor, RON-IN-1) is a potent inhibitor of human c-Met and RON with IC50 of 4 nM and 9 nM, respectively. |
| M20652 | JNJ-38877618 | JNJ-38877618 (OMO-1) is a potent, highly selective, orally bioavailable MET kinase inhibitor with binding affinity (Kd) of 1.4 nM and enzyme inhibitory activity against wt and M1268T mutant MET (2 and 3 nM IC50). |
| M20606 | SAR125844 | SAR125844 is a potent intravenously active and highly selective MET kinase inhibitor, displaying nanomolar activity against the wild-type kinase (IC50 value of 4.2 nmol/L) and H1094Y, Y1235D, M1250T, L1195V, and D1228H kinase domain mutants (IC50 values of 0.22, 1.7, 6.5, 65, and 81 nmol/L, respectively). |
| M20167 | WAY-354831 | WAY-354831 is a inhibitor of c-Met kinase. |
| M20063 | WAY-298041 | WAY-298041 is a c-Met inhibitor. |
| M20046 | WAY-271999 | WAY-271999 is a c-Met kinase inhibitor |
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
